A Meta-analysis for Prevalence of Lung Cancer Patients with
SARS-CoV-2 Infection during the COVID-19 Pandemic

Asadian, Fatemeh; NATAJ, Mohsen Gholi; Neamatzadeh, Hossein; MİRJALİLİ, Hamid; VAKİLİ, Mohammad; DASTGİRİ, Ahmad Shirinzadeh; RAFIEIAN, Shahab; ERSHADİ, Reza; BARAHMAN, Maedeh

doi:10.14744/ejmo.2022.50535

A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic

Mohsen Gholi NATAJ, (Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran)

Shahab RAFIEIAN, (Department of Thoracic Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran)

Maedeh BARAHMAN, (Firoozgar Clinical Research Development Center (FCRDC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran)

Ahmad Shirinzadeh DASTGİRİ, (Department of Surgery, Faculty of Medicine, Shohadaye Hafte-e-tie hospital, Iran University of Medical Sciences, Tehran, Iran)

Mohammad VAKİLİ, (Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran)

Reza ERSHADİ, (Department of Thoracic Surgery, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran)

Hamid MİRJALİLİ, (Department of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran)

Fatemeh ASADİAN, (Department of Emergency Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran)

Hossein NEAMATZADEH (Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran)

Eurasian Journal of Medicine and Oncology

2 1

Yıl: 2022 Cilt: 6 Sayı: 1 Sayfa Aralığı: 73 - 82 Metin Dili: İngilizce DOI: 10.14744/ejmo.2022.50535 İndeks Tarihi: 18-06-2022

A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic

Öz:

Objectives: Cancer patients were found to be at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced more adverse outcomes. The objective of this meta-analysis was to estimate the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic. Methods: A comprehensive search was carried out on PubMed, Web of Science, Scopus, MedRxiv, SciELO, SID, CNKI, and Wanfang databases to retrieve all relevant publications. All cross-sectional studies and consecutive case series on cancer patients with SARS-CoV-2 infection were selected. A total of 28 studies including 5400 infected cancer patients and 767 lung cancer patients with COVID-19 were included. Results: Combined data indicated that the prevalence of lung cancer patients with SARS-CoV-2 infection was 15.2% (95% CI, 0.111–0.205) overall. Stratified analysis by ethnicity showed that the prevalence was 16.4% and 15.4% in Asian and Caucasian lung cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that the prevalence was highest in China (19.3.0%) followed by France (12.6%), the UK (10.7%), and the USA (8.3%). Conclusion: This meta-analysis revealed that the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 15.2%.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, Abbasi H, Mirjalili SR, Behforouz A, et al. Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review. Fetal Pediatr Pathol 2020;39:246–50.
2. Noorishadkam M, Lookzadeh MH, Mazaheri M, Mirjalili SR, Bahrami R, Asadian F, et al. Coronavirus Disease 2019 (COVID- 19) and late pregnancy loss in infected pregnant women: a mini review. WJPN 2020;2:67–70.
3. Mirjalili H, Dastgheib SA, Shaker SH, Bahrami R, Mazaheri M, Sadr-Bafghi SMH, et al. Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis. J Diabetes Metab Disord 2021;20:905–17.
4. Sayad S, Ahmadi SAY, Nekouian R, Panahi M, Anbari K. Epidemiological and pathological characteristics of post-surgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study. Arch Oncol 2020;26:6–9.
5. Coronavirus Disease (COVID-19) Situation Reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus- 2019/situation-reports. Accessed Apr 5, 2021.
6. Cancarevic I, Tathineni P, Malik BH. Coronavirus Disease 2019 (COVID-19) in cancer patients. Cureus 2020;12:e7835.
7. Leung TF, Wong GW, Hon KL, Fok TF. Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management. Paediatr Respir Rev 2003;4:334–9
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
9. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV- 2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91–5.
10. de Marinis F, Attili I, Morganti S, Stati V, Spitaleri G, Gianoncelli L, et al. Results of multilevel containment measures to better protect lung cancer patients from COVID-19: The IEO model. Front Oncol 2020;10:665.
11. Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, et al. The immuno-oncological challenge of COVID- 19. Nat Cancer 2020;1:946–4.
12. Milionis C, Milioni SO. A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus. J Diabetes Metab Disord 2020;19:2035–9.
13. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther 2020;5:128.
14. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? a review of potential options for therapeutic intervention. Front Immunol 2019;10:2247.
15. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783–91.
16. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020;43:452–5.
17. Sayad S, Ahmadi SAY, Moradi M, Nekouian R, Anbari K, Shahsavar F. A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer. Expert Rev Precis Med Drug Dev 2020;5:109–14.
18. Jyotsana N, King MR. The impact of COVID-19 on cancer risk and treatment. Cel Mol Bioeng 2020;13:285–91.
19. Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep 2020;22:53.
20. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al; COVID-19 and cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395:1907–18.
21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
22. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARSCoV- 2 (Covid-19). J Clin Med 2020;9:841.
23. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 2021;116:1319–68.
24. Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8:542–4.
25. Liao Z, Rivin Del Campo E, Salem A, Pang Q, Liu H, Lopez Guerra JL. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer 2020;146:230–5.
26. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: A meta-analysis of patient data. JCO Global Oncology 2020:799–808.
27. Baghestani AR, Shahmirzalou P, Sayad S, Akbari ME, Zayeri F. Comparison cure rate models by DIC criteria in breast cancer data. Asian Pac J Cancer Prev 2018;19:1601–6.
28. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919–26.
29. Mahmood TB, Chowdhury AS, Hossain MU, Hasan M, Mizan S, Aakil MM, et al. Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. Curr Res Microb Sci 2021;2:100022.
30. Jarahzadeh MH, Asadian F, Farbod M, Meibodi B, Abbasi H, Jafari M, et al. Cancer and Coronavirus Disease (COVID-19): comorbidity, mechanical ventilation, and death risk. J Gastrointest Cancer 2021;52:80–4.
31. Antikchi MH, Neamatzadeh H, Ghelmani Y, Jafari-Nedooshan J, Dastgheib SA, Kargar S, et al. The risk and prevalence of COVID- 19 infection in colorectal cancer patients: a systematic review and meta-analysis. J Gastrointest Cancer 2021;52:73–9.
32. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna- Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020;10:935–41.
33. Ahmadi SAY, Sayad S, Shahsavar F, Nekouian R, Panahi M, Sayad S, et al. Expression of angiogenesis-related genes in a group of Iranian cases of breast cancer. Curr Pharmacogenomics Person Med 2021;17:197–205.
34. Behtash N, Zarchi MK, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pac J Cancer Prev 2009;10:613–8.
35. Mousavi A, Karimi Zarchi M, Gilani MM, Behtash N, Ghaemmaghami F, Shams M, et al. Radical hysterectomy in the elderly. World J Surg Oncol 2008;6:38.
36. Ghaemmaghami F, Zarchi MK, Gilani MM, Mousavi A, Behtash N, Ghasemi M. Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran. Asian Pac J Cancer Prev 2008;9:421–6.
37. Khoram-Abadi KM, Forat-Yazdi M, Kheirandish S, Saeidi N, Zarezade Z, Mehrabi N, et al. DNMT3B -149 C>T and -579 G>T polymorphisms and risk of gastric and colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev 2016; 17:3015–20.
38. Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020;126:4023–31.
39. Wang J, Song Q, Chen Y, Wang Z, Chu Q, Gong H, et al. Systematic investigations of COVID-19 in 283 cancer patients. MedRxiv. 2020 May 3. Doi: https://doi.org/10.1101/2020.04.28.2008. [Epub ahead of print].
40. Ali J, Sajjad K, Farooqi AR, Aziz MT, Rahat A, Khan S. COVID- 19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes. Hematol Oncol Stem Cell The. 2021;14:311–7.
41. Aznab M. Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic. Int J Clin Oncol 2020;25:1581–6.
42. Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Cancer Res 2020;80:CT403.
43. Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr 2021;5:pkaa090.
44. Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARSCOV- 2 on RT-PCR. Eur J Cancer 2020;135:251–9.
45. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al; TERAVOLT investigators. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21:914–22.
46. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26:1218–23.
47. Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol 2020;38:3538–46.
48. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92:2067–73.
49. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020;31:1088–9.
50. Kabarriti R, Brodin NP, Maron MI, Tomé WA, Halmos B, Guha C, et al. Extent of prior lung irradiation and mortality in COVID-19 patients with a cancer history. Adv Radiat Oncol 2020;5:707– 10.
51. Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, et al. Factors affecting COVID-19 Outcomes in cancer patients: a first report from Guy's Cancer Center in London. Front Oncol 2020;10:1279.
52. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol2020; 21:1309–16.
53. Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study. Eur J Cancer 2020;139:181–7.
54. Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol 2020;16:1425–32.
55. Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo- Loureiro A, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 2020;135:242–50.
56. de Melo AC, Thuler LCS, da Silva JL, de Albuquerque LZ, Pecego AC, Rodrigues L de OR, et al. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute. PLos One 2020;15:e0241261.
57. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13.
58. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:893– 903.
59. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020;6:1108–10.
60. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.
61. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894–901.
62. Zhang Y, Li M, Gan L, Li B. Analysis of clinical characteristics of 5 tumor patients with coronavirus disease 2019. Guangdong Med J 2020;41.
63. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study. J Infect 2020;81:318–56.
64. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395:1763–70.
65. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: Prospective cohort study. BMJ 2020;369:m1923.
66. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020;217:e20200678.
67. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39:405–7.
68. Peravali M, Joshi I, Ahn J, Kim C. A Systematic review and meta- analysis of clinical characteristics and outcomes in patients with lung cancer with coronavirus disease 2019. JTO Clin Res Rep 2021;2:100141.
69. Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020;31:1386–96.
70. Venkatesulu BP, Chandrasekar VT, Girdhar P, Advani P, Sharma A, Elumalai T, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv. 2020 May 29. Doi: 10.1101/2020.05.27.20115303. [Epub ahead of print].
71. Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol 2020;153:103032.

APA	NATAJ M, RAFIEIAN S, BARAHMAN M, DASTGİRİ A, VAKİLİ M, ERSHADİ R, MİRJALİLİ H, Asadian F, Neamatzadeh H (2022). A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. , 73 - 82. 10.14744/ejmo.2022.50535
Chicago	NATAJ Mohsen Gholi,RAFIEIAN Shahab,BARAHMAN Maedeh,DASTGİRİ Ahmad Shirinzadeh,VAKİLİ Mohammad,ERSHADİ Reza,MİRJALİLİ Hamid,Asadian Fatemeh,Neamatzadeh Hossein A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. (2022): 73 - 82. 10.14744/ejmo.2022.50535
MLA	NATAJ Mohsen Gholi,RAFIEIAN Shahab,BARAHMAN Maedeh,DASTGİRİ Ahmad Shirinzadeh,VAKİLİ Mohammad,ERSHADİ Reza,MİRJALİLİ Hamid,Asadian Fatemeh,Neamatzadeh Hossein A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. , 2022, ss.73 - 82. 10.14744/ejmo.2022.50535
AMA	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. . 2022; 73 - 82. 10.14744/ejmo.2022.50535
Vancouver	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. . 2022; 73 - 82. 10.14744/ejmo.2022.50535
IEEE	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H "A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic." , ss.73 - 82, 2022. 10.14744/ejmo.2022.50535
ISNAD	NATAJ, Mohsen Gholi vd. "A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic". (2022), 73-82. https://doi.org/10.14744/ejmo.2022.50535

APA	NATAJ M, RAFIEIAN S, BARAHMAN M, DASTGİRİ A, VAKİLİ M, ERSHADİ R, MİRJALİLİ H, Asadian F, Neamatzadeh H (2022). A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. Eurasian Journal of Medicine and Oncology, 6(1), 73 - 82. 10.14744/ejmo.2022.50535
Chicago	NATAJ Mohsen Gholi,RAFIEIAN Shahab,BARAHMAN Maedeh,DASTGİRİ Ahmad Shirinzadeh,VAKİLİ Mohammad,ERSHADİ Reza,MİRJALİLİ Hamid,Asadian Fatemeh,Neamatzadeh Hossein A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. Eurasian Journal of Medicine and Oncology 6, no.1 (2022): 73 - 82. 10.14744/ejmo.2022.50535
MLA	NATAJ Mohsen Gholi,RAFIEIAN Shahab,BARAHMAN Maedeh,DASTGİRİ Ahmad Shirinzadeh,VAKİLİ Mohammad,ERSHADİ Reza,MİRJALİLİ Hamid,Asadian Fatemeh,Neamatzadeh Hossein A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. Eurasian Journal of Medicine and Oncology, vol.6, no.1, 2022, ss.73 - 82. 10.14744/ejmo.2022.50535
AMA	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 73 - 82. 10.14744/ejmo.2022.50535
Vancouver	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 73 - 82. 10.14744/ejmo.2022.50535
IEEE	NATAJ M,RAFIEIAN S,BARAHMAN M,DASTGİRİ A,VAKİLİ M,ERSHADİ R,MİRJALİLİ H,Asadian F,Neamatzadeh H "A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic." Eurasian Journal of Medicine and Oncology, 6, ss.73 - 82, 2022. 10.14744/ejmo.2022.50535
ISNAD	NATAJ, Mohsen Gholi vd. "A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic". Eurasian Journal of Medicine and Oncology 6/1 (2022), 73-82. https://doi.org/10.14744/ejmo.2022.50535